Medications Development for the Treatment of Cannabis Related Disorders (MTC)
2012年5月31日 更新者:University of Virginia
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
研究概览
详细说明
Stress (emotional, physical, social) facilitates drug seeking behavior through the activation of the HPA axis, autonomic nervous system, and brain DA systems.
Furthermore, alterations within several neuropeptide systems (CRF, Substance P, and others) also contribute to the role of stress in addiction.
Central to this project is that anxiety and stress responses are modulated by substance P and its preferred target, the NK1 receptor.
Therefore the aim of this pilot clinical trial is to determine the safety and efficacy of aprepitant (a neurokinin 1 (NK1) receptor antagonist).
We hypothesize that the NK1 receptor antagonist, aprepitant, will be safe, tolerable and efficacious at reducing the withdrawal symptoms, cue craving, and reinforcement value for both cannabis and tobacco resulting from the cessation of either or both drugs.
We will assess this hypothesis in the context of a carefully controlled human laboratory study in which subjects (N=72) will be randomized in a 3 x 2 factorial design to one of 3 behavioral conditions; a) withdrawn from both substances, b) withdrawn from tobacco only, or c) withdrawn from cannabis only, and to receive one of 2 medication dose conditions: placebo or aprepitant (160 mg/day).
Medication will be administered for 5 days, followed by a cue challenge, choice procedure, and then a consequence (i.e., oral cannabis or a cigarette or money) also on day 5.
研究类型
介入性
注册 (实际的)
63
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- Clinical Pharmacological Research Unit (CPRU), University of Virginia School of Medicine
-
Charlottesville、Virginia、美国、22908
- University of Virginia Center for Addiction Education and Treatment (UVA CARE)
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 45年 (成人)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Must meet DSM-IV/ICD-10 criteria for cannabis abuse or dependence
- Must be non-treatment seeking individuals
- Participant does not meet DSM-IV criteria for any current (i.e., criteria met at any point in the past 30 days) dependence on a substance other than alcohol, nicotine, caffeine, or marijuana or physiological dependence on alcohol requiring medical detoxification.
- No subjects who have trouble reading the English language or visual or hearing problems that may interfere with the collection of data
- Not currently taking other medications (with the exception of oral contraceptives) that would preclude safe participation in this study
- Must test negative for pregnancy prior to inclusion
- females using birth control pills must agree to use a condom during intercourse for 1 month after participation in study because the study medication will decrease the effectiveness of the birth control pill rendering it ineffective
- Should be in general good health
- No evidence of recent use of other illicit drugs on a urine toxicity screen prior to admission
Exclusion Criteria:
- Major current (within last 90 days) Axis I psychopathology (e.g., major depressive disorder, bipolar disorder, schizophrenia)
- Presence of significant medical illness (e.g., diabetes, cardiovascular disease, hypertension, cancer, epilepsy, kidney disease)
- Current, repeated illicit drug use (other than marijuana)
- Subject is breastfeeding or pregnant
- Concurrent therapy with drugs known to inhibit CYP3A4 activity
- Request for drug treatment
- Current parole or probation
- Recent history of significant violent or suicide behavior
- Allergic to sesame oil
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Behavioral Condition 1
Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
|
Placebo Aprepitant 0 mg once daily for 5 days
Active Aprepitant 160 mg once daily for 5 days
|
|
实验性的:Behavioral Condition 2
Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
|
Placebo Aprepitant 0 mg once daily for 5 days
Active Aprepitant 160 mg once daily for 5 days
|
|
实验性的:Behavioral Condition 3
Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
|
Placebo Aprepitant 0 mg once daily for 5 days
Active Aprepitant 160 mg once daily for 5 days
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
withdrawal symptom severity, measured on a 0 (not at all) to 3 (severe) scale
大体时间:collected on each study day
|
Subjective experience of withdrawal symptoms for cannabis, tobacco, and both (eg: Irritability, Sleep difficulty, Chills, Nervousness)
|
collected on each study day
|
|
"craving" measured using the Marijuana craving questionaire and the tobacco craving questionaire
大体时间:collected on each study day
|
Subjective measures of craving for cannabis, tobacco, and both Questionaires are anchored with strongly disagree to strongly agree (1-7)
|
collected on each study day
|
|
reinforcing effects, as measured using the Multiple Choice Questionaire
大体时间:collected each day of study
|
Reinforcement value of cannabis and tobacco as measured by preference for money over the administration of either drug; questionaire has 70 questions and money value vs. drug ranges from 25 cents to 25 dollars 1-70.
|
collected each day of study
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
sleep quality
大体时间:collected on each study day
|
A VAS sleep questionnaire will be used each morning to assess daily sleep quality.
|
collected on each study day
|
|
Neurocognitive Function
大体时间:collected on days 1-4 of the study
|
The purpose of examining the neurocognitive function of our participants on days 1-4 is to examine the safety of the co-administration of aprepitant at 160 mg/day with oral THC (dronabinol 10 mg) on brain function.
Tasks used are the DSST - The Digit Symbol Substitution Test measures the learning of integrating visual and motor skills, and the SRTT- The Simple reaction Time Task is a well validated computerized test for assessing the effects of psychoactive drugs on performance.
|
collected on days 1-4 of the study
|
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
大体时间:each day of study
|
Blood pressure, pulse, and a Systematic Assessment For Treatment Emergent Events (SAFTEE) are collected daily.
Electrocardiograms (EKGs) are collected at baseline and discharge.
|
each day of study
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Heather M Haughey, Ph.D.、University of Virginia School of Medicine, Dept. Psychiatry and Neurobehavioral Sciences
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2009年8月1日
初级完成 (实际的)
2012年1月1日
研究完成 (实际的)
2012年4月1日
研究注册日期
首次提交
2010年9月14日
首先提交符合 QC 标准的
2010年9月15日
首次发布 (估计)
2010年9月17日
研究记录更新
最后更新发布 (估计)
2012年6月1日
上次提交的符合 QC 标准的更新
2012年5月31日
最后验证
2012年5月1日
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 14392
- R01DA027131 (美国 NIH 拨款/合同)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.